Walgreens Boots Alliance (WBA) Issues FY18 Earnings Guidance
Walgreens Boots Alliance (NASDAQ:WBA) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $5.45-5.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56.
Walgreens Boots Alliance (NASDAQ:WBA) opened at $75.51 on Thursday. Walgreens Boots Alliance has a 12-month low of $63.82 and a 12-month high of $88.00. The firm has a market capitalization of $74,227.16, a PE ratio of 19.98, a P/E/G ratio of 1.34 and a beta of 1.22. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.59 and a current ratio of 1.07.
Walgreens Boots Alliance (NASDAQ:WBA) last released its earnings results on Thursday, January 4th. The pharmacy operator reported $1.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.04. The firm had revenue of $30.74 billion for the quarter, compared to the consensus estimate of $30.39 billion. Walgreens Boots Alliance had a return on equity of 18.36% and a net margin of 3.45%. The firm’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.10 earnings per share. analysts predict that Walgreens Boots Alliance will post 5.54 EPS for the current fiscal year.
Walgreens Boots Alliance declared that its board has approved a share repurchase program on Wednesday, October 25th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the pharmacy operator to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.
A number of equities analysts have recently commented on WBA shares. Jefferies Group restated a buy rating and issued a $95.00 price objective on shares of Walgreens Boots Alliance in a report on Thursday, September 7th. Needham & Company LLC restated a buy rating and issued a $94.00 price objective on shares of Walgreens Boots Alliance in a report on Sunday, September 10th. BidaskClub downgraded Walgreens Boots Alliance from a hold rating to a sell rating in a report on Tuesday, September 12th. Royal Bank of Canada started coverage on Walgreens Boots Alliance in a report on Tuesday, September 19th. They issued an outperform rating and a $96.00 price objective on the stock. Finally, Raymond James Financial restated a market perform rating on shares of Walgreens Boots Alliance in a report on Wednesday, September 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $86.60.
In other Walgreens Boots Alliance news, Director John Anthony Lederer acquired 20,000 shares of the stock in a transaction on Thursday, October 26th. The stock was purchased at an average price of $67.00 per share, for a total transaction of $1,340,000.00. Following the purchase, the director now directly owns 50,000 shares in the company, valued at $3,350,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William C. Foote sold 2,736 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $67.37, for a total value of $184,324.32. Following the sale, the director now owns 16,415 shares of the company’s stock, valued at approximately $1,105,878.55. The disclosure for this sale can be found here. Company insiders own 14.80% of the company’s stock.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.